ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania.
All News
Article
Article
The content at ACR Orlando was vast. I looked at several posters/listened to many talks and heard from colleagues. Here is my list TOP 6 practice changing themes.
Article
Obesity, in particular in psoriatic arthritis (PsA) was widely covered at #ACR26. This is from the recognition of the size of the problem.
Biologics vs JAKi: MACE and VTE Risk in PsA
Dr. Sheila Reyes & Dr. Marina Magrey | Abstract 2304 | ACR 2026
https://t.co/IzafHHg9Me https://t.co/PGfQOk882R
Two Prescriptions, One Patient
Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
Falls Hide in Plain Sight in Rheumatic Disease
A patient with arthritis pitches forward onto her knees and wrists while bending to grab something. Another time she tries to get up and lands on the bed. Another time she uses a chair to lower herself to the floor.
By the World https://t.co/kmmaRxhII0
Biologic Dosing and Obesity
A 46-year-old with pSa and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Stephen Balevic, MD, PhD, discusses this question in "Prescribing the Right Dose: How Obesity Alters Drug https://t.co/0SGQGs32U2
Are GLP-1s Doing More Than Shrinking Waistlines in PsA?
In abstract #0373, Pankti Mehta and colleagues examined patients from a longitudinal PsA cohort who initiated GLP-1 receptor agonist or dual GIP/GLP-1 therapy and compared them with matched controls. Baseline body mass https://t.co/FGCszLnS4N
Antoni Chan MD (Prof)
Tweet
ACR26 summary, AI and documentation: errors on all five AI platforms tested against guidelines, and cDAPSA documented in 4.9% of PsA records @rheumnow #ACR26 Abstract#0869 Abstract#1348
Antoni Chan MD (Prof)
Tweet
ACR26 summary, obesity in PsA: 81.8% prevalence of overweight or obesity in a US cohort, lower ACR50 at higher BMI on bimekizumab, and higher ACR50 with ixekizumab plus tirzepatide at 52 weeks. @rheumnow #ACR26 Abstract#2015 Abstract#1305 Abstract#2942
Antoni Chan MD (Prof)
Tweet
In the phase 2a AFFINITY study of 91 patients with PsA and inadequate response to TNF inhibition, guselkumab plus golimumab reduced the TNF activity score, CRP and IL6, while guselkumab alone showed numerical reductions only. Responders to combination therapy had higher baseline https://t.co/E9gEb8sN2j
sheila
Tweet
Biomarker data on Ph2 Affinity Study (Gus+Gol vs Gus) in PsA
Combi Gus+Gol and mono Gus significantly reduced sIL-17A/F & BD2 levels
Gus+Gol decr CRP, IL-6 & TNG activity thru wk 24
@RheumNow #ACR26 Abs2943 https://t.co/n1dxn0EREy
sheila
Tweet
Some practical key points to consider for D2M/TR axSpA:
MisDx & mimics
Dx re-evaluation: Hx, PE, rpt imaging if needed
Confirm inflamm act w/ imaging
Tx Adherence
EAMs
Co-morbidities mimicking SpA - inflamm vs noci pain?
Damage
Indiv strategies for TR axSpA
@RheumNow #ACR Abs2944 https://t.co/kXhdhkLnkR
David Liew
Tweet
Great @RheumNow Day 2 Daily Recap today talking about trends in SpA therapy, PsA and obesity, gout flares and CV risk, IL-17/23 in PMR/GCA, and as always a healthy dose of 'AI is coming/here'. All the good stuff from #ACR26 with @synovialjoints @AdelaCastro222 @ericdeinmd https://t.co/FSjr2Qn3JC
sheila
Tweet
52 wk data of TOGETHER-PsA: Ixe + Tzp for PsA
Ixe+Tzp achieved ACR50 resp & change in body wt thru 52wks; noted superiority by 36wks vs Ixe alone; greater dse control, wt, & metabolic control
AEs comparable w/ wk 36 results.
Low GI d/c rates
@RheumNow #ACR26 Abs2942 https://t.co/MorFe1A4OZ
Akhil Sood MD, MS
Tweet
VTE risk by inflammatory arthritis (RA, AS, PsA)
Abstract 2925:
- VTE incidence rate IA vs ctrl (8.21 vs 3.66 per 1,000 person-yrs) w/ nearly 2 fold inc risk
- Highest risk w/ RA (aHR 2.22)
- Vs RA, AS risk lower (aHR 0.83) & no diff w PsA (aHR 0.86, 0.72-1.02)
@RheumNow #ACR26 https://t.co/IH8FGSf9yg
A2942 TOGETHER-PsA (NCT06588296) Phase 3b, with obese pts
Tirzepatide + Ixekizumab combo beat Ixe alone at 52 wks
ACR50 43.7% vs 15.7%
Weight -20.4% vs -0.6%
But 37% of ixe-alone stop Rx vs 20% on combo
Target weight and inflammation control in PsA
@RheumNow #ACR26 https://t.co/pqfTm2hbwZ
Audrey Gibson
Tweet
Merola et al. (TOGETHER-PsA): At week 52, ACR50, MDA, DAPSA and hsCRP favored ixekizumab + tirzepatide. Encouraging, but longer-term safety, durability and generalizability still matter. @rheumnow #ACR2026 Abstract#2942 https://t.co/VhjmrtgVsr
Audrey Gibson
Tweet
Merola et al. (TOGETHER-PsA): The most provocative PsA finding at ACR2026? Treating inflammation alone may leave a modifiable contributor to symptoms and outcomes unaddressed. TOGETHER-PsA offers randomized evidence to discuss. @rheumnow #ACR2026 Abstract#2942
Audrey Gibson
Tweet
TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942
